Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-10-20 Purchase | 2020-10-22 4:31 pm | Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner | 200,000 | $15 | $3,000,000 | 2,614,563 (Direct) | View |
| 2020-10-20 Purchase | 2020-10-20 5:00 pm | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 200,000 | $15 | $3,000,000 | 862,444 (Indirect) | View |
| 2020-10-20 Purchase | 2020-10-20 4:59 pm | Aligos Therapeutics Inc. | ALGS | Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner | 550,000 | $15 | $8,250,000 | 430,372 (Indirect) | View |
| 2020-10-20 Purchase | 2020-10-20 4:58 pm | Aligos Therapeutics Inc. | ALGS | Versant Venture Capital VI L.P. Versant Vantage I L.P. 10% Owner | 200,000 | $15 | $3,000,000 | 3,292,339 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-06-23 Option Award | 2022-06-27 4:14 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-06-23 Option Award | 2022-06-27 4:14 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Hirth Peter Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-06-23 Option Award | 2022-06-27 4:13 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-06-23 Option Award | 2022-06-27 4:13 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Nielsen Jack Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-06-23 Option Award | 2022-06-27 4:12 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Nuechterlein Carole Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-06-23 Option Award | 2022-06-27 4:11 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Martell Bridget A Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2022-04-27 Ownership | 2022-05-06 4:12 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | McClure Matthew W. Chief Medical Officer | 0 | $0 | 515,478 (Indirect) | View |
| 2022-02-08 Option Award | 2022-02-08 4:09 pm | N/A 2032-02-04 | Aligos Therapeutics Inc. | ALGS | Symons Julian A. See Remarks | 131,250 | $0 | 131,250 (Direct) | View |
| 2022-02-04 Option Award | 2022-02-08 4:09 pm | N/A 2032-02-04 | Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE CEO | 404,250 | $0 | 404,250 (Direct) | View |
| 2022-02-04 Option Award | 2022-02-08 4:08 pm | N/A 2032-02-04 | Aligos Therapeutics Inc. | ALGS | Calhoun Lesley Ann See Remarks | 131,250 | $0 | 131,250 (Direct) | View |
| 2022-02-04 Option Award | 2022-02-08 4:07 pm | N/A 2032-02-04 | Aligos Therapeutics Inc. | ALGS | Quan Lucinda Y. See Remarks | 131,250 | $0 | 131,250 (Direct) | View |
| 2022-02-04 Option Award | 2022-02-08 4:07 pm | N/A 2032-02-04 | Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President | 283,500 | $0 | 283,500 (Direct) | View |
| 2021-11-16 Option Award | 2021-11-18 4:38 pm | N/A 2031-11-16 | Aligos Therapeutics Inc. | ALGS | Martell Bridget A Director | 30,000 | $0 | 30,000 (Direct) | View |
| 2021-06-17 Option Award | 2021-06-17 6:46 pm | N/A 2031-06-17 | Aligos Therapeutics Inc. | ALGS | Nielsen Jack Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2021-06-17 Option Award | 2021-06-17 5:14 pm | N/A 2031-06-17 | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2021-06-17 Option Award | 2021-06-17 5:13 pm | N/A 2031-06-17 | Aligos Therapeutics Inc. | ALGS | Hirth Peter Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2021-06-17 Option Award | 2021-06-17 5:09 pm | N/A 2031-06-17 | Aligos Therapeutics Inc. | ALGS | Nuechterlein Carole Director | 15,000 | $0 | 15,000 (Direct) | View |
| 2021-06-11 Other | 2021-06-15 4:43 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 506,307 | $0 | 1,391,305 (Indirect) | View |
| 2021-04-26 Other | 2021-04-28 5:00 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 506,310 | $0 | 1,389,085 (Indirect) | View |
| 2021-04-26 Option Award | 2021-04-27 4:42 pm | N/A 2031-04-26 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 30,000 | $0 | 30,000 (Direct) | View |
| 2020-12-01 Option Award | 2020-12-03 8:05 pm | N/A 2030-12-01 | Aligos Therapeutics Inc. | ALGS | Symons Julian A. See Remarks | 200,000 | $0 | 200,000 (Direct) | View |
| 2020-12-01 Option Award | 2020-12-03 8:04 pm | N/A 2030-12-01 | Aligos Therapeutics Inc. | ALGS | Calhoun Lesley Ann See Remarks | 176,237 | $0 | 176,237 (Direct) | View |
| 2020-12-01 Option Award | 2020-12-03 8:04 pm | N/A 2030-12-01 | Aligos Therapeutics Inc. | ALGS | Quan Lucinda Y. See Remarks | 200,000 | $0 | 200,000 (Direct) | View |
| 2020-12-01 Option Award | 2020-12-03 8:03 pm | N/A 2030-12-01 | Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President | 300,000 | $0 | 300,000 (Direct) | View |
| 2020-12-01 Option Award | 2020-12-03 8:03 pm | N/A 2030-12-01 | Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE CEO | 450,000 | $0 | 450,000 (Direct) | View |
| 2020-10-20 Conversion | 2020-10-22 4:31 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner | 4,829,126 | $0 | 2,614,563 (Direct) | View |
| 2020-10-20 Conversion | 2020-10-22 4:12 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 1,906,191 | $0 | 1,906,191 (Direct) | View |
| 2020-10-20 Conversion | 2020-10-20 5:00 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 3,092,339 | $0 | 862,444 (Indirect) | View |
| 2020-10-20 Conversion | 2020-10-20 4:59 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner | 2,997,030 | $0 | 430,372 (Indirect) | View |
| 2020-10-20 Conversion | 2020-10-20 4:58 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Versant Venture Capital VI L.P. Versant Vantage I L.P. 10% Owner | 3,092,339 | $0 | 3,292,339 (Direct) | View |
| 2020-10-20 Conversion | 2020-10-20 4:57 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Symons Julian A. See Remarks | 18,517 | $0 | 394,064 (Direct) | View |
| 2020-10-20 Conversion | 2020-10-20 4:56 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Quan Lucinda Y. See Remarks | 9,258 | $0 | 384,805 (Indirect) | View |
| 2020-10-20 Conversion | 2020-10-20 4:55 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Nuechterlein Carole Director | 3,092,340 | $0 | 3,092,340 (Indirect) | View |
| 2020-10-20 Conversion | 2020-10-20 4:55 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE CEO | 273,058 | $0 | 1,255,815 (Indirect) | View |
| 2020-10-20 Conversion | 2020-10-20 4:53 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President | 273,057 | $0 | 1,255,650 (Indirect) | View |
| 2020-10-15 Ownership | 2020-10-15 7:50 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 0 | $0 | 1,906,191 (Direct) | View |
| 2020-10-15 Ownership | 2020-10-15 7:16 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner | 0 | $0 | 2,414,563 (Direct) | View |
| 2020-10-15 Ownership | 2020-10-15 5:17 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director | 0 | $0 | 3,092,339 (Indirect) | View |